Citizens maintains Option Care Health stock rating on potential acquisition talks
Citizens analyst reiterated a Market Outperform rating and $32.00 price target for Option Care Health (OPCH), citing potential acquisition talks with McKesson and CD&R. The stock trades at $23.37, below the target and fair value estimates. A deal could value OPCH at $27-$29 per share, with McKesson and CD&R acquiring 49% and 51% respectively. OPCH reported Q2 earnings beating estimates, with revenue of $1.44B and EPS of $0.45. Analysts have mixed views on the stock's future.
How this was made
The 30-second read
Why it matters
The acquisition talk is the primary new catalyst, likely driving OPCH toward the $27‑$29 valuation range and prompting modest re‑rating of McKesson.
Market read
A newly disclosed $5B+ acquisition involving OPCH and McKesson provides a clear short‑term trading catalyst for OPCH and a secondary consideration for McKesson.
What to watch
Potential antitrust review, financing terms for CD&R, and the impact of biosimilar pressure on OPCH's chronic inflammatory disease segment.
Background
Citizens analyst maintains a $32 price target on OPCH, noting the stock trades well below this level. The article also references recent earnings beat and mixed analyst opinions.
Ticker impact
Citizens reiterates a Market Outperform rating on Option Care Health after a Financial Times report that McKesson and CD&R are in advanced talks to acquire the company in a $5B+ deal.
upward pressure as the market prices in the potential $5B acquisition at $27‑$29 per share.
The deal is newly disclosed, sizable, and includes a concrete per‑share valuation that exceeds the current price.
McKesson is named as a potential acquirer of Option Care Health in the same $5B+ transaction, making it a direct party to the deal.
slight upward pressure as investors anticipate synergies from the acquisition of Option Care Health.
While McKesson benefits from the deal, the primary catalyst is the target's stock; McKesson's own price move is expected to be limited.
Market effects
The deal highlights consolidation in the specialty pharmacy and infusion services sector, potentially prompting valuation reassessments for peers.
U.S. healthcare and specialty drug distribution markets may see modest re‑rating as the transaction underscores strategic importance of integrated services.
Limited to U.S. healthcare investors; no broader macro impact.
Counterpoint
If regulatory scrutiny or integration challenges arise, the deal could stall, leaving OPCH shares vulnerable to a pull‑back.
Key entities
- CompanyOption Care Health
U.S. specialty infusion services provider, ticker OPCH.
- CompanyMcKesson
Large U.S. drug distributor, ticker MCK.
- Private EquityClayton Dubilier & Rice
PE firm partnering with McKesson in the acquisition.
